Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Looking for participantsNCT07092202
What this trial is testing

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Who this might be right for
Leptomeningeal MetastasisNSCLCIntrathecal Chemotherapy+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40
Testing effectiveness (Phase 2)WithdrawnNCT02785068
What this trial is testing

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Merrimack Pharmaceuticals
Not applicableEnded earlyNCT00898027
What this trial is testing

Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer

Who this might be right for
Solid Tumor
Vanderbilt-Ingram Cancer Center 10
Not applicableUnknownNCT03916913
What this trial is testing

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Chinese Academy of Medical Sciences 85
Testing effectiveness (Phase 2)UnknownNCT03666325
What this trial is testing

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

Who this might be right for
Skin Neoplasm
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 43
Large-scale testing (Phase 3)Study completedNCT00404924
What this trial is testing

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Who this might be right for
Non-Small-Cell Lung Carcinoma
Genzyme, a Sanofi Company 1,140
Testing effectiveness (Phase 2)Study completedNCT00039182
What this trial is testing

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Who this might be right for
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant Mesothelioma+1 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Ended earlyNCT03222622
What this trial is testing

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Who this might be right for
Mild to Moderate Psoriasis
Betta Pharmaceuticals Co., Ltd. 136
Early research (Phase 1)Study completedNCT01586624
What this trial is testing

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Who this might be right for
CancerNon Small Cell Lung Cancer
Cancer Research UK 61
Very early researchStudy completedNCT03471364
What this trial is testing

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

Who this might be right for
Malignant Neoplasm
Mayo Clinic 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Testing effectiveness (Phase 2)Ended earlyNCT00739063
What this trial is testing

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00977548
What this trial is testing

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
H. Lee Moffitt Cancer Center and Research Institute 39
Testing effectiveness (Phase 2)Study completedNCT02442349
What this trial is testing

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 171
Testing effectiveness (Phase 2)Looking for participantsNCT06830863
What this trial is testing

Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Who this might be right for
EGFR Inhibitor-associated Rash
Azitra Inc. 32
Early research (Phase 1)Study completedNCT01647711
What this trial is testing

Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 35
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Testing effectiveness (Phase 2)Ended earlyNCT04820023
What this trial is testing

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Who this might be right for
NSCLC
Bridge Biotherapeutics, Inc. 45
Not applicableUnknownNCT01775943
What this trial is testing

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Who this might be right for
Lung Neoplasms
Ulsan University Hospital 90
Next Page